HOME >> MEDICINE >> NEWS
Rutgers-Newark researcher discovers new motor protein mechanism linked to heart disease and strokes

Cardiomyopathy is an insidious disease which often strikes without warning and can lead to heart failure and eventual death. Although the disease can be traced to conditions such as high blood pressure, heart valve or arterial diseases and congenital heart defects, it is also caused by viral infections in the bloodstream. In a paper to be published in the July issue of the journal Nature Structural and Molecular Biology, a Rutgers-Newark researcher and his coworkers reveal that they have identified a possible mechanism used by an important motor protein which acts as a catalyst that enables bacteria outside the human body to travel through the blood stream and infect organs such as the heart.

The findings were published by Rutgers-Newark Chemistry Assistant Professor Charalampos Kalodimos and his coworkers, in the article, "Disorder-order folding transitions underlie catalysis in the helicase motor of SecA." Identifying the way this motor protein works is significant because it may lead to the development of new pharmacological therapies which can target and kill the bacteria to prevent or minimize damage to the heart muscle. The results follow nearly two years of research funded by a $300,000 American Heart Association (AHA) grant. The AHA agreed to support Kalodimos's research because he is focusing on specific bacteria that cause cardiovascular diseases in both adults and children.

Using high-resolution NMR Spectroscopy technology, Kalodimos identified the mechanism of function of motor protein SecA, which uses chemical energy and converts it into mechanical energy. SecA is present only in bacteria and is not found in humans. SecA uses mechanical energy to secrete toxins and other harmful proteins to the exterior of the bacterium cell.

Once a bacterium infects a human or a host, some bacteria will use the SecA system to secrete specific bacteria proteins into the human body causing infections or diseases. Recent advances in NMR Spectroscopy a
'"/>

Contact: Peter Haigney
phaigney@andromeda.rutgers.edu
973-353-1663
Rutgers, the State University of New Jersey
20-Jul-2006


Page: 1 2

Related medicine news :

1. Rutgers-Newark psychology researchers reveal link between body and action perception
2. Learning software developed by Rutgers-Newark scientist helps 450,000 students with reading
3. Stanford researchers find culprit in aging muscles that heal poorly
4. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
5. Penn researchers discover novel pathway for increasing good cholesterol
6. Theory of facial aging gets a facelift from UT Southwestern researchers
7. UIC researchers to develop new drugs to fight bioterrorism
8. Fat is the new normal, FSU researcher says
9. UQ researchers discover some of the oldest forms of life
10. U of M researchers discover new method to combat HIV
11. K-State researcher working on a way to make snack foods with extra fiber

Post Your Comments:
(Date:6/19/2013)... treating stroke victims has been "time equals brain." That,s because ... a drug that dissolves the stroke-causing blood clot can make ... or lost. , But specific information has been ... drug known as a tissue plasminogen activator, or tPA ... most common type of stroke. , Now, a ...
(Date:6/19/2013)... Loyola University Chicago Niehoff School of Nursing researcher has ... Vitamin D can improve mood in women with diabetes ... whether vitamin D supplementation can reduce blood pressure and ... is from the National Institute of Nursing Research at ... M. Penckofer, PhD, RN and colleagues hypothesize that women ...
(Date:6/19/2013)... 19, 2013 AquaPrint Solutions in Thomson, IL ... Grub with a newly-designed Harley Davidson motorcycle gas tank. A ... Solutions with an idea of taking a split tank motorcycle ... and transforming it into a work of art. , ... Grub several toilet seats that had been dipped in a ...
(Date:6/19/2013)... FL (PRWEB) June 19, 2013 Fit Body ... Andrea Laing recently held a charity boot camp in order ... fibrosis. The fitness boot camp franchise hosted the ... to 11 a.m. with 75 boot camp participants and collected ... charity boot camp marks the second fundraiser held for Orlando ...
(Date:6/19/2013)... Salt Lake City, UT (PRWEB) June 19, 2013 ... their expanded BRCA1 and BRCA2 testing service , ... genes. Analysis is available individually, or as part of ... up to seventeen additional genes with known links to ... TP53, CDK4, STK11, SMAD4, BMPR1A, CDH1, MET, FH, FLCN, ...
Breaking Medicine News(10 mins):Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:Loyola receives $1.5 million grant to study vitamin D for diabetes and depression 2Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2Health News:Fit Body Boot Camp in Orlando Held Successful “Brent Can Breathe” Charity Boot Camp with Proceeds Going to Support Orlando Local Brent Snyder with Cystic Fibrosis 2Health News:Ethigen Launches Next Generation (NGS) BRCA Testing With Expanded Hereditary Cancer Panel 2Health News:Ethigen Launches Next Generation (NGS) BRCA Testing With Expanded Hereditary Cancer Panel 3
(Date:6/19/2013)... June 19, 2013   Voices Against Brain Cancer ... cure for brain cancer, today announced that it has ... support the clinical investigation of Toca 511 & Toca ... glioma brain cancer (Grade 3 or Grade 4).  Tocagen ... for advanced cancer, with an initial focus on brain ...
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... Nektar Therapeutics (Nasdaq: NKTR ) today announced ... for NKTR-181, a first-in-class, opioid analgesic molecule with ... rate of entry is designed to reduce the euphoria that ... opioid analgesics. 1 In the study data being presented ... "drug liking" and "feeling high" scores and had highly statistically ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9
Cached News: